Home › Funds › ALGERT GLOBAL LLC › XENE

ALGERT GLOBAL LLC position in XENE

XENON PHARMACEUTICALS INC · Health Care

ALGERT GLOBAL LLC reported holding 419,773 shares of XENE (XENON PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$25.3M, representing 0.30% of its reported portfolio and ranking #46 among its reported holdings. ALGERT GLOBAL LLC has disclosed XENE holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)419.77K sh
Reported value held$25.34M
Portfolio Weight0.30%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How ALGERT GLOBAL LLC's XENE position evolved

ALGERT GLOBAL LLC first disclosed a stake in XENE in Q3 2023 at 128,487 shares (US$4.4M). The position peaked in Q2 2026 at 419,773 shares, worth US$25.3M. Across 12 filings, ALGERT GLOBAL LLC increased the stake 6 time(s), trimmed it 4 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 419,773 shares valued at US$25.3M — an increase of 155,573 shares quarter over quarter.. Notable position changes include a 69% increase in Q4 2023 (shares fell 7% over the following quarter), a 127% increase in Q4 2025 (shares rose 30% over the following quarter), a 114% increase in Q1 2026 (shares rose 4% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 128.49K $4.39M New
Q4 2023 217.32K $10.01M Add
Q1 2024 184.01K $7.92M Reduce
Q2 2024 183.21K $7.14M Hold
Q3 2024 219.65K $8.65M Add
Q4 2024 241.42K $9.46M Add
Q1 2025 123.42K $4.14M Reduce
Q2 2025 102.34K $3.20M Reduce
Q3 2025 54.26K $2.18M Reduce
Q4 2025 123.19K $5.52M Add
Q1 2026 264.20K $15.36M Add
Q2 2026 419.77K $25.34M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About XENE and 13F data

XENE (XENON PHARMACEUTICALS INC) is a Health Care company. 44 other funds we track also report a position in XENE — the largest reported positions include Avoro Capital Advisors LLC (US$348.7M), Polar Capital Holdings Plc (US$275.9M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$266.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding XENE

All XENE fund holders →

FAQ

How long has ALGERT GLOBAL LLC held XENE?

ALGERT GLOBAL LLC has disclosed XENE holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is ALGERT GLOBAL LLC's current position in XENE?

As of Q2 2026, ALGERT GLOBAL LLC holds 419.77K shares of XENE (XENON PHARMACEUTICALS INC), valued at $25.34M, representing 0.30% of its reported portfolio and ranking #46.

Has ALGERT GLOBAL LLC been buying or selling XENE?

In the latest 13F filing (Q2 2026), ALGERT GLOBAL LLC increased its position in XENE. The position peaked in Q2 2026 at 419.77K shares.

Which other funds hold XENE?

Other major institutional holders of XENE include Avoro Capital Advisors LLC, Polar Capital Holdings Plc, DRIEHAUS CAPITAL MANAGEMENT LLC, among 44 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.